英文名稱：Cellartis DEF-CS 500 Xeno-Free Culture Medium without Antibiotics

中文名稱：Cellartis DEF-CS?500?無外源?iPS?培養(yǎng)基，不含抗生素

特點：不含抗生素，無飼養(yǎng)層，非酶法單細胞傳代。

用途：臨床前級別iPS細胞生產(chǎn)

保存：基礎(chǔ)培養(yǎng)基2-8°C，添加劑-20°C

?

Cellartis DEF-CS 500 Xeno-Free Culture Medium 不含抗生素，適用于在完全不含人和動物來源組分的條件下擴增人誘導(dǎo)多能干（iPS）細胞。細胞不使用飼養(yǎng)層細胞的情況下培養(yǎng)；而是使用諸如iMatrix-511的無異源物基底。培養(yǎng)方案使用溫和的非酶促單細胞傳代以確保可控制性和重復(fù)性。Cellartis DEF-CS?500無動物源培養(yǎng)基（不含抗生素）中培養(yǎng)的細胞具有高增殖率和穩(wěn)定的核型，適合有效擴增。這些特性的結(jié)合使得該培養(yǎng)基成為再生醫(yī)學研究臨床前級別iPS細胞生產(chǎn)的理想選擇。

?

特點：

不含人類或動物來源成分

優(yōu)化用于培養(yǎng)臨床前級人類iPS細胞

保留了iPS細胞的多能性和長期的自我更新和分化潛能

提供高重復(fù)性和穩(wěn)定的生長

使用單細胞傳代方法

?

組份：基礎(chǔ)培養(yǎng)基+添加劑

Cellartis DEF-CS Xeno-Free Culture Medium without Antibiotics (Cat. No. Y30045)

500 ml Cellartis DEF-CS 500 Xeno-Free Basal Medium without Antibiotics (Cat. No Y30046; not?sold separately)

Cellartis DEF-CS 500 Xeno-Free Additives (Cat. No. Y30042)

o 500 μl DEF-CS Xeno-Free Additive 1 (1000X)

o 200 μl DEF-CS Xeno-Free Additive 2 (1000X)

?

另行購買試劑：

緩沖液、培養(yǎng)基質(zhì)和消化劑

PBS Dulbecco’s（含鈣鎂和不含鈣鎂）和細胞培養(yǎng)基質(zhì)

Corning Synthemax II-SC Substrate (Corning, Cat. No. 3535) or iMatrix-511 (Takara Clontech, Cat. No. T303)

PBS Dulbecco’s with Ca2+ & Mg2+ (D-PBS +/+)

PBS Dulbecco’s w/o Ca2+ & Mg2+ (D-PBS –/–)

Versene Solution (Life Technologies, Cat. No. 15040)

Cellartis DEF-CS 500 Xeno-Free Culture Medium without Antibiotics is intended for the expansion of human induced pluripotent stem (iPS) cells in conditions that are completely free from human- and animal-derived components. Cells are cultured in the absence of feeder cells; instead, a xeno-free substrate such as iMatrix-511 is used. The culture protocol uses gentle, non-enzymatic single-cell passaging to ensure controlled and reproducible conditions. Cells cultured in Cellartis DEF-CS 500 Xeno-Free Culture Medium without Antibiotics have a high-proliferation rate and stable karyotype, allowing for efficient scale-up. The combination of these features makes this medium ideal for generating preclinical-grade iPS cells for regenerative medicine studies.